• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Mild COVID-19 symptoms despite treatment with teriflunomide and high-dose methylprednisolone due to multiple sclerosis relapse.

作者信息

Möhn Nora, Saker Firas, Bonda Viktoria, Respondek Gesine, Bachmann Marcus, Stoll Matthias, Wattjes Mike P, Stangel Martin, Skripuletz Thomas

机构信息

Department of Neurology, Hannover Medical School, Hannover, Germany.

Department of Rheumatology and Immunology, Hannover Medical School, Hannover, Germany.

出版信息

J Neurol. 2020 Oct;267(10):2803-2805. doi: 10.1007/s00415-020-09921-1. Epub 2020 May 28.

DOI:10.1007/s00415-020-09921-1
PMID:32494855
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7268187/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cd1/7268187/7d20de2aba30/415_2020_9921_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cd1/7268187/7d20de2aba30/415_2020_9921_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cd1/7268187/7d20de2aba30/415_2020_9921_Fig1_HTML.jpg

相似文献

1
Mild COVID-19 symptoms despite treatment with teriflunomide and high-dose methylprednisolone due to multiple sclerosis relapse.尽管因多发性硬化症复发接受了特立氟胺和高剂量甲泼尼龙治疗，但仍出现轻度新冠症状。
J Neurol. 2020 Oct;267(10):2803-2805. doi: 10.1007/s00415-020-09921-1. Epub 2020 May 28.
2
COVID-19 in teriflunomide-treated patients with multiple sclerosis.新冠肺炎在多发性硬化症接受特立氟胺治疗的患者中。
J Neurol. 2020 Oct;267(10):2790-2796. doi: 10.1007/s00415-020-09944-8. Epub 2020 Jun 3.
3
COVID-19 in MS: Initial observations from the Pacific Northwest.多发性硬化症中的新冠病毒病：来自美国太平洋西北地区的初步观察
Neurol Neuroimmunol Neuroinflamm. 2020 May 26;7(5). doi: 10.1212/NXI.0000000000000783. Print 2020 Sep 3.
4
Combination of teriflunomide and interferon as follow-up therapy after fingolimod-associated PML.特立氟胺与干扰素联合用于芬戈莫德相关进行性多灶性白质脑病后的后续治疗
Neurol Neuroimmunol Neuroinflamm. 2020 Dec 3;8(1). doi: 10.1212/NXI.0000000000000927. Print 2021 Jan.
5
B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran.B 细胞耗竭疗法可能会影响伊朗 COVID-19 疫情早期多发性硬化症患者急性呼吸道疾病的易感性。
Mult Scler Relat Disord. 2020 Aug;43:102195. doi: 10.1016/j.msard.2020.102195. Epub 2020 May 13.
6
Dihydroorotate dehydrogenase inhibitors in SARS-CoV-2 infection.二氢乳清酸脱氢酶抑制剂在新冠病毒感染中的作用
Eur J Clin Invest. 2020 Oct;50(10):e13366. doi: 10.1111/eci.13366. Epub 2020 Aug 16.
7
Favorable outcome after COVID-19 infection in a multiple sclerosis patient initiated on ocrelizumab during the pandemic.一名多发性硬化症患者在大流行期间开始使用奥瑞珠单抗治疗，感染新冠病毒后预后良好。
Mult Scler Relat Disord. 2020 Aug;43:102222. doi: 10.1016/j.msard.2020.102222. Epub 2020 May 23.
8
COVID-19 pneumonia in a multiple sclerosis patient with severe lymphopenia due to recent cladribine treatment.新冠病毒肺炎在一名多发性硬化症患者中发作，该患者由于最近接受克拉屈滨治疗而出现严重的淋巴细胞减少症。
Mult Scler. 2020 Sep;26(10):1264-1266. doi: 10.1177/1352458520943783. Epub 2020 Aug 7.
9
Efficacy and safety of teriflunomide in Asian patients with relapsing forms of multiple sclerosis: A subgroup analysis of the phase 3 TOWER study.特立氟胺治疗亚洲复发型多发性硬化患者的疗效和安全性：3期TOWER研究的亚组分析
J Clin Neurosci. 2019 Jan;59:229-231. doi: 10.1016/j.jocn.2018.09.012. Epub 2018 Oct 20.
10
An updated review of teriflunomide's use in multiple sclerosis.特立氟胺在多发性硬化症中的应用的最新综述。
Neurodegener Dis Manag. 2021 Oct;11(5):387-409. doi: 10.2217/nmt-2021-0014. Epub 2021 Sep 16.

引用本文的文献

1
Immune responses following COVID-19 infection in multiple sclerosis patients using immunomodulatory therapy.COVID-19 感染后使用免疫调节疗法的多发性硬化症患者的免疫反应。
Acta Neurol Belg. 2023 Oct;123(5):1885-1892. doi: 10.1007/s13760-022-02125-6. Epub 2022 Nov 4.
2
COVID-19 and the risk of CNS demyelinating diseases: A systematic review.2019冠状病毒病与中枢神经系统脱髓鞘疾病风险：一项系统评价
Front Neurol. 2022 Sep 20;13:970383. doi: 10.3389/fneur.2022.970383. eCollection 2022.
3
Teriflunomide Treatment of Multiple Sclerosis Selectively Modulates CD8 Memory T Cells.

本文引用的文献

1
How is immunosuppressive status affecting children and adults in SARS-CoV-2 infection? A systematic review.免疫抑制状态如何影响 SARS-CoV-2 感染中的儿童和成人？系统评价。
J Infect. 2020 Jul;81(1):e61-e66. doi: 10.1016/j.jinf.2020.04.026. Epub 2020 Apr 23.
2
Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis.危重症和死亡 COVID-19 病例的风险因素：系统文献回顾和荟萃分析。
J Infect. 2020 Aug;81(2):e16-e25. doi: 10.1016/j.jinf.2020.04.021. Epub 2020 Apr 23.
3
15-day mortality and associated risk factors for hospitalized patients with COVID-19 in Wuhan, China: an ambispective observational cohort study.
特立氟胺治疗多发性硬化症选择性调节 CD8 记忆 T 细胞。
Front Immunol. 2021 Oct 5;12:730342. doi: 10.3389/fimmu.2021.730342. eCollection 2021.
4
Multiple Sclerosis, Disease-Modifying Therapies and COVID-19: A Systematic Review on Immune Response and Vaccination Recommendations.多发性硬化症、疾病修正疗法与2019冠状病毒病：关于免疫反应和疫苗接种建议的系统综述
Vaccines (Basel). 2021 Jul 11;9(7):773. doi: 10.3390/vaccines9070773.
5
Anti-inflammatory Therapy by Cholinergic and Purinergic Modulation in Multiple Sclerosis Associated with SARS-CoV-2 Infection.新型冠状病毒肺炎相关多发性硬化症中胆碱能和嘌呤能调节的抗炎治疗
Mol Neurobiol. 2021 Oct;58(10):5090-5111. doi: 10.1007/s12035-021-02464-0. Epub 2021 Jul 11.
6
The Epidemiology of COVID-19 and MS-Related Characteristics in a National Sample of People With MS in China.中国全国多发性硬化症患者样本中新冠病毒肺炎的流行病学及与多发性硬化症相关的特征
Front Neurol. 2021 May 28;12:682729. doi: 10.3389/fneur.2021.682729. eCollection 2021.
7
Drugs Used in the Treatment of Multiple Sclerosis During COVID-19 Pandemic: A Critical Viewpoint.COVID-19 大流行期间治疗多发性硬化症的药物：批判性观点。
Curr Neuropharmacol. 2022;20(1):107-125. doi: 10.2174/1570159X19666210330094017.
8
COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: A systematic review.COVID-19 与中枢神经系统脱髓鞘疾病患者的疾病修正治疗：系统评价。
Mult Scler Relat Disord. 2021 May;50:102800. doi: 10.1016/j.msard.2021.102800. Epub 2021 Jan 29.
9
SARS-CoV-2/COVID-19 in multiple sclerosis patients receiving disease-modifying therapy.接受疾病修正治疗的多发性硬化症患者中的 SARS-CoV-2/COVID-19。
Clin Neurol Neurosurg. 2021 Feb;201:106451. doi: 10.1016/j.clineuro.2020.106451. Epub 2020 Dec 29.
10
Experience in Multiple Sclerosis Patients with COVID-19 and Disease-Modifying Therapies: A Review of 873 Published Cases.多发性硬化症合并 COVID-19 患者及疾病修正治疗的经验：873 例已发表病例的综述
J Clin Med. 2020 Dec 16;9(12):4067. doi: 10.3390/jcm9124067.
中国武汉新冠肺炎住院患者的15天死亡率及相关危险因素：一项双向观察性队列研究
Intensive Care Med. 2020 Jul;46(7):1472-1474. doi: 10.1007/s00134-020-06047-w. Epub 2020 Apr 23.
4
Coronaviruses and Immunosuppressed Patients: The Facts During the Third Epidemic.冠状病毒与免疫抑制患者：第三次疫情期间的实际情况
Liver Transpl. 2020 Jun;26(6):832-834. doi: 10.1002/lt.25756. Epub 2020 Apr 24.
5
Intravenous pulse methylprednisolone for induction of remission in severe ANCA associated Vasculitis: a multi-center retrospective cohort study.静脉注射脉冲甲基强的松龙诱导严重抗中性粒细胞胞浆抗体相关性血管炎缓解：一项多中心回顾性队列研究。
BMC Nephrol. 2019 Feb 18;20(1):58. doi: 10.1186/s12882-019-1226-0.
6
Association of baseline steroid use with long-term rates of infection and sepsis in the REGARDS cohort.基线类固醇使用与 REGARDS 队列中感染和败血症的长期发生率之间的关联。
Crit Care. 2017 Jul 13;21(1):185. doi: 10.1186/s13054-017-1767-1.
7
Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study.沙特阿拉伯 47 例中东呼吸综合征冠状病毒病的流行病学、人口统计学和临床特征：描述性研究。
Lancet Infect Dis. 2013 Sep;13(9):752-61. doi: 10.1016/S1473-3099(13)70204-4. Epub 2013 Jul 26.
8
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.多发性硬化症的诊断标准：2010 年麦克唐纳标准修订版。
Ann Neurol. 2011 Feb;69(2):292-302. doi: 10.1002/ana.22366.